Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...